Quinone-to-Quinol Reduction Compositions for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing reduced forms of quinones and quinols, such as ubiquinol from ubiquinone, are limited, and there is a need for new methods to address specific health conditions and improve bioavailability and absorption of these compounds.
Innovation Solution
Compositions and methods are developed for preparing quinols from quinones, including ubiquinol from ubiquinone, using specific chemical moieties and solvents, and formulations for oral administration to enhance bioavailability and absorption, suitable for treating various health conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current methods for preparing reduced forms of quinones and quinols are used, then the preparation process is simple, but the bioavailability and absorption are insufficient
Solution Approach 1:
The patent changes the chemical parameters of the preparation process by using specific reducing agents (ascorbic acid, dithiothreitol, tris(2-carboxyethyl)phosphine) and controlling pH conditions to optimize the reduction of quinones to quinols, thereby improving bioavailability while maintaining reasonable manufacturing complexity
Solution Approach 2:
The patent employs composite formulations combining quinone/quinol with auxiliary substances such as phospholipids, fatty acids, and proteins to create composite materials that enhance absorption and bioavailability through synergistic effects
2Reliability
If quinone is converted to quinol form, then the reduced state is achieved for specific health conditions, but the preparation methods are limited
Solution Approach 1:
The patent develops a universal preparation methodology that can be applied to multiple quinone compounds (ubiquinone, menaquinone, plastoquinone) using the same reducing agents and protocols, thereby achieving versatility while reliably producing the required reduced quinol forms for various health conditions
3Quantity of substance
If oral formulations are developed to enhance absorption, then the bioavailability improves, but the formulation complexity increases
Solution Approach 1:
The patent introduces intermediary substances such as phospholipids, fatty acids, and proteins that act as mediators to facilitate the absorption of quinol compounds in oral formulations, improving bioavailability while managing formulation complexity through the use of naturally occurring substances
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed compositions effectively increase the bioavailability and absorption of quinols, addressing health conditions like statin-induced CoQ10 depletion, cardiac function, and improving metabolic synthesis and mitochondrial function.
Implementation Method 1
ubiquinol (CAS 992-78-9; C59H92O4; molecular weight: 865) is the reduced state of ubiquinone
Implementation Method 2
CoQnol-CoQone redox pair
Data Source
AI summary
The present embodiments are directed to compositions of quinones and/or quinols, such as, but not limited to, ubiquinone and/or ubiquinol, vitamin E quinone and/or vitamin E quinol, vitamin K quinone and/or vitamin K quinol, menaquinones and/or menaquinols, and pyrroloquinoline quinone and/or pyrroloquinoline quinol, and methods for preparations and use thereof. The present embodiments are also directed to compositions of reduced forms of curcuminoid and methods for preparations and use thereof.